Filing summary
Entity discrepancy: The request identifies Accendra Health Inc., but the supplied Form 10-Q is for Owens & Minor, Inc. (NYSE: OMI). This summary reflects the filing provided, for the quarter ended March 31, 2024.
Business context and reporting period
Owens & Minor operates two segments: Products & Healthcare Services, comprising medical distribution, logistics, and medical-surgical products; and Patient Direct, comprising home healthcare businesses Byram and Apria. Financial statements are unaudited and compare Q1 2024 with Q1 2023.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Net revenue | $2,612.7 million | $2,522.8 million; up 3.6% |
| Gross profit / margin | $535.5 million / 20.50% | $497.3 million / 19.71% |
| Operating income | $9.7 million | $9.8 million |
| Net loss / diluted loss per share | $(21.9) million / $(0.29) | $(24.4) million / $(0.32) |
| Interest expense, net | $35.7 million | $42.2 million |
| Cash from operating activities | $(53.0) million | $158.4 million |
| Cash used for investing activities | $(1.9) million | $(34.2) million |
| Cash from (used for) financing activities | $53.3 million | $(127.5) million |
| Cash and cash equivalents | $244.9 million | $243.0 million at December 31, 2023 |
| Total debt | $2,153.7 million | $2,097.5 million at December 31, 2023 |
| Current assets / current liabilities | $2,236.3 million / $1,933.1 million | $2,102.8 million / $1,891.9 million at December 31, 2023 |
Cash, cash equivalents and restricted cash totaled $270.8 million at quarter-end. The company reported $423 million available under its revolving credit facility, net of letters of credit, and said it was in compliance with debt covenants. Capital expenditures were $49.4 million. Operating cash flow was pressured by working-capital movements, including higher receivables and inventory.
Changes versus the prior comparable period
- Revenue increased 3.6%. Products & Healthcare Services revenue grew 3.1%; Patient Direct grew 5.0%.
- Gross margin improved 0.79 percentage points, while operating income was nearly flat. Higher DS&A and exit and realignment costs offset much of the gross-profit improvement.
- Products & Healthcare Services segment operating income rose to $11.5 million from $1.8 million; Patient Direct segment operating income was essentially unchanged at $45.9 million.
- Net loss narrowed by $2.5 million, with lower interest expense contributing to the improvement. The company said foreign currency translation reduced Q1 2024 earnings per share by $0.02 year over year.
- Operating cash flow swung from $158.4 million provided to $53.0 million used, largely reflecting unfavorable working-capital changes compared with favorable changes in the prior-year quarter.
Outlook, commentary, risks and unusual items
- The filing provides no specific revenue or earnings guidance. Management said cash from operations, receivables programs, available credit facilities, and cash on hand should be sufficient for foreseeable needs, while noting economic conditions could affect financing access and costs.
- Exit and realignment charges were $27.4 million, including $34.7 million of charges related to the Operating Model Realignment Program and IT initiatives, partially offset by a $7.4 million gain on the headquarters sale. Management expects material future program costs but cannot reasonably estimate them.
- Apria supplier Philips Respironics’ device recall remains a risk. Philips entered a consent decree in April 2024 restricting certain production and distribution until FDA requirements are met. Owens & Minor reported ongoing recall-related costs, some of which may not be recoverable, and warned other supply disruptions could materially affect results, cash flows, or liquidity.
- $171 million of 4.375% senior notes is due in December 2024. The filing also describes cross-default provisions and substantial debt obligations; refinancing and repayment capacity merit monitoring.
- The company sold $515 million of receivables under a separate purchase agreement in Q1 and received $512 million of net cash proceeds; the reported loss on sales, including related professional fees, was $3.3 million. This supports cash availability but has a cost and affects working-capital measures.
- The IRS is challenging transfer-pricing positions for tax years 2015–2018. Management believes reserves are adequate and does not expect a material impact, but notes an adverse outcome could materially affect the company.
- Management considers pending legal matters’ probable-loss accruals not material and sufficient. A $48.4 million lease commitment for a Morgantown facility had been signed but had not commenced.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Owens & Minor, not Accendra Health.
- Assess the December 2024 notes’ repayment or refinancing plan and the company’s leverage, interest costs, and covenant headroom.
- Reconcile the filing’s receivables-financing disclosures: it reports $65.7 million of principal outstanding (with $64.4 million carrying value) but also states there were no borrowings at quarter-end; clarify the balance and available capacity.
- Track working-capital conversion and operating cash flow, including the effects of receivables sales and rising DSO and inventory days.
- Monitor future restructuring and IT initiative costs, Philips recall-related exposures, and the outcome of the IRS tax dispute.